{"id":26344,"date":"2026-08-03T08:40:11","date_gmt":"2026-08-03T12:40:11","guid":{"rendered":"https:\/\/medicarereport.org\/?p=26344"},"modified":"2026-08-03T08:40:12","modified_gmt":"2026-08-03T12:40:12","slug":"medicares-proposed-cut-to-340b-drug-payments-would-hit-safety-net-hospitals-while-benefiting-for-profit-hospitals","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=26344","title":{"rendered":"Medicare\u2019s Proposed Cut to 340B Drug Payments Would Hit Safety-Net Hospitals While Benefiting For-Profit Hospitals"},"content":{"rendered":"\n

(Authors: Scott Hulver, Zachary Levinson, Juliette Cubanski, and Meredith Freed for The Kaiser Family Foundation Published: Jul 29, 2026)<\/p>\n\n\n\n

The recently proposed 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule from the Centers for Medicare & Medicaid Services (CMS) includes a proposal to reduce Medicare\u2019s reimbursement for 340B drugs. The proposal would reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 33.4%, a 37% reduction. CMS indicated that this change would better align Medicare reimbursement with hospitals\u2019 costs of acquiring 340B drugs. Continue reading here…<\/a><\/p>\n\n\n\n

\"\"<\/p>\n\n\n\n

Notice:<\/strong>\u00a0The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/p>\n","protected":false},"excerpt":{"rendered":"

(Authors: Scott Hulver, Zachary Levinson, Juliette Cubanski, and Meredith Freed for The Kaiser Family Foundation Published: Jul 29, 2026) The<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[32,21,6,15],"tags":[433,80,385,238,65],"class_list":["post-26344","post","type-post","status-publish","format-standard","hentry","category-cms","category-health-care-finance","category-medicare-general","category-part-dprescription-drugs","tag-340b-drug-discount-program","tag-cms","tag-healthcare-costs","tag-healthcare-finance","tag-medicare-part-d"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/26344","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=26344"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/26344\/revisions"}],"predecessor-version":[{"id":26345,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/26344\/revisions\/26345"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=26344"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=26344"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=26344"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}